- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
GLP-1 RA Use Linked to Lower Hematologic Cancer Risk in T2D Patients: JAMA

According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) was associated with a reduced risk of developing hematologic cancers compared to insulin and metformin use.
Type 2 diabetes (T2D) and obesity are independent risk factors for various cancers, including hematologic cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained attention for their role in glycemic control, weight loss, and immune modulation. While they are associated with lower risks of solid tumors, their impact on hematologic cancers remains unclear.
This study aims to compare hematologic cancer risks in T2D patients treated with GLP-1RAs versus metformin and insulin. Using data from the TriNetX electronic health record platform, a retrospective cohort study was conducted, including 1,601,334 T2D patients prescribed GLP-1RAs, metformin, or insulin between 2005 and 2023. Patients were excluded if they had prior hematologic cancer diagnoses or used antidiabetic medications before their T2D diagnosis. The primary outcome was the first diagnosis of hematologic cancer within 15 years.
Propensity score matching was performed to control for demographic and clinical variables. After matching, 47,716 patients were included in the GLP-1RA–insulin comparison and 50,590 in the GLP-1RA–metformin comparison. GLP-1RA use was associated with a significantly lower risk of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) compared to metformin. Compared to insulin, GLP-1RAs significantly reduced risks of multiple hematologic cancers, including myeloid and lymphoid leukemia, non-Hodgkin lymphoma, multiple myeloma, and amyloidosis.
The study suggests that GLP-1RAs may lower hematologic cancer risk, potentially due to weight loss and immunomodulatory effects. The protective effect appears independent of glycemic control and may be linked to reduced proinflammatory cytokines. While metformin has potential cancer-protective properties, its effects were less pronounced than GLP-1RAs. Study limitations include reliance on medical codes, residual confounding, and lack of age stratification. Further research is needed to explore the biological mechanisms underlying GLP-1RA-associated cancer risk reduction.
Reference:
Ashruf OS, Hundal J, Mushtaq A, Kaelber DC, Anwer F, Singh A. Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists. JAMA Netw Open. 2025;8(3):e250802. doi:10.1001/jamanetworkopen.2025.0802
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751